MX2021013491A - Nuevas endolisinas de gardnerella y usos de las mismas. - Google Patents

Nuevas endolisinas de gardnerella y usos de las mismas.

Info

Publication number
MX2021013491A
MX2021013491A MX2021013491A MX2021013491A MX2021013491A MX 2021013491 A MX2021013491 A MX 2021013491A MX 2021013491 A MX2021013491 A MX 2021013491A MX 2021013491 A MX2021013491 A MX 2021013491A MX 2021013491 A MX2021013491 A MX 2021013491A
Authority
MX
Mexico
Prior art keywords
endolysins
disorders
diseases
treating
present
Prior art date
Application number
MX2021013491A
Other languages
English (en)
Inventor
Lorenzo Corsini
Original Assignee
Phagomed Biopharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phagomed Biopharma Gmbh filed Critical Phagomed Biopharma Gmbh
Publication of MX2021013491A publication Critical patent/MX2021013491A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)

Abstract

La presente invención se refiere a nuevas endolisinas de fago selectivas de especies y su uso para tratar la vaginosis bacteriana (VB). La presente invención proporciona endolisinas recombinantes, es decir endolisinas de dominio intercambiado. La invención también se refiere a dichas endolisinas para su uso en el tratamiento de enfermedades o trastornos, tales como infecciones bacterianas, en particular VB. La invención se refiere además a polinucleótidos que codifican dichas endolisinas. Dichos polinucleótidos también se pueden usar para tratar tales enfermedades o trastornos. La presente invención también proporciona una composición farmacéutica que comprende una endolisina de la invención para su uso en el tratamiento de tales enfermedades o trastornos. Dichas endolisinas, polinucleótidos y composición farmacéutica pueden administrarse localmente, en particular localmente dentro de la vagina.
MX2021013491A 2019-05-08 2020-05-07 Nuevas endolisinas de gardnerella y usos de las mismas. MX2021013491A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19173389 2019-05-08
PCT/EP2020/062645 WO2020225335A1 (en) 2019-05-08 2020-05-07 Novel gardnerella endolysins and uses thereof

Publications (1)

Publication Number Publication Date
MX2021013491A true MX2021013491A (es) 2022-02-21

Family

ID=66476422

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013491A MX2021013491A (es) 2019-05-08 2020-05-07 Nuevas endolisinas de gardnerella y usos de las mismas.

Country Status (14)

Country Link
US (1) US20220315908A1 (es)
EP (1) EP3969578A1 (es)
JP (1) JP2022532130A (es)
KR (1) KR20220007123A (es)
CN (1) CN113795577A (es)
AU (1) AU2020268752A1 (es)
BR (1) BR112021022283A2 (es)
CA (1) CA3136346A1 (es)
CL (1) CL2021002901A1 (es)
IL (1) IL287842A (es)
MA (1) MA55951A (es)
MX (1) MX2021013491A (es)
SG (1) SG11202111067YA (es)
WO (1) WO2020225335A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022105998A1 (en) * 2020-11-18 2022-05-27 CC Biotech Ltd. Polypeptides for treatment of bacterial infections
WO2023083434A1 (en) * 2021-11-09 2023-05-19 BioNTech SE Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
WO2023152298A1 (en) 2022-02-11 2023-08-17 BioNTech SE Novel therapeutic uses of gardnerella endolysins

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202556D0 (en) * 2002-02-04 2002-03-20 Danisco Novel Protein
AU2008328584A1 (en) * 2007-11-26 2009-06-04 Plant Bioscience Limited Novel polypeptides having endolysin activity and uses thereof
US20120171188A1 (en) * 2008-08-19 2012-07-05 Hyglos Invest Gmbh Artificial Peptidoglycan Lysing Enzymes and Peptidoglycan Binding Proteins
GB0815484D0 (en) * 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
AU2010288559B8 (en) * 2009-08-24 2015-08-13 Katholieke Universiteit Leuven, K.U. Leuven R&D New endolysin OBPgpLYS
EP2338916A1 (en) * 2009-12-23 2011-06-29 Hyglos Invest GmbH Chimeric polypeptides and their use in bacterial decoloniation
SG184836A1 (en) * 2010-04-27 2012-11-29 Lysando Ag Method of reducing biofilms
GB201018518D0 (en) * 2010-11-03 2010-12-15 Univ Leuven Kath Novel endolysin
US8790639B2 (en) * 2012-03-28 2014-07-29 The United States Of America, As Represented By The Secretary Of Agriculture Enhanced antimicrobial lytic activity of a chimeric Ply187 endolysin
CN105062992B (zh) * 2015-07-20 2018-05-11 昆明理工大学 一种细胞内溶素和编码此细胞内溶素的多核苷酸
KR20200012844A (ko) * 2017-04-03 2020-02-05 사시나파스 컴퍼니 리미티드 조작된 그람-음성 엔도리신
CN111471671B (zh) * 2020-04-16 2022-04-12 中国农业大学 一种具有抑制产气荚膜梭菌活性的蛋白质及其相关生物材料与应用
WO2023152298A1 (en) * 2022-02-11 2023-08-17 BioNTech SE Novel therapeutic uses of gardnerella endolysins

Also Published As

Publication number Publication date
WO2020225335A1 (en) 2020-11-12
AU2020268752A1 (en) 2021-12-02
SG11202111067YA (en) 2021-11-29
JP2022532130A (ja) 2022-07-13
MA55951A (fr) 2022-03-23
BR112021022283A2 (pt) 2021-12-28
CL2021002901A1 (es) 2022-06-03
EP3969578A1 (en) 2022-03-23
IL287842A (en) 2022-01-01
CN113795577A (zh) 2021-12-14
CA3136346A1 (en) 2020-11-12
KR20220007123A (ko) 2022-01-18
US20220315908A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
MX2021013491A (es) Nuevas endolisinas de gardnerella y usos de las mismas.
MX2022015812A (es) Inhibidores de cisteina proteasas y sus metodos de uso.
WO2017191274A3 (en) Rna encoding a therapeutic protein
GB2480773B (en) Compositions for the treatment of diarrhea caused by virulent E. coli infections
NZ627372A (en) Clostridium histolyticum enzymes and methods for the use thereof
MX2020013853A (es) Compuestos innovadores.
HRP20050903A2 (en) Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
BR112023020442A2 (pt) Inibidor da protease 1 específica de ubiquitina (usp1)
MX2019013799A (es) Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo.
CO2021016323A2 (es) Composiciones útiles en el tratamiento de leucodistrofia metacromática
MX2021009696A (es) Vectores de genoterapia para el tratamiento de la enfermedad de danon.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
CR20210507A (es) Composición farmacéutica acuosa de anticuerpo anti-il17a y su uso
MX2021013356A (es) Tratamiento y prevencion de enfermedades metabolicas.
ZA202204938B (en) Enhancement and stabilisation of proteolytic activity of proteases
SG10201908089VA (en) Novel dosing regimens of celgosivir for the treatment of dengue
EA202091308A1 (ru) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
MX2017002476A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular.
EP4223304A3 (en) Novel antimicrobial and anti-cancer therapy
MX2022000433A (es) Proteinas de fusion a toxina para el tratamiento de enfermedades relacionadas con infecciones por cmv.
AR106739A1 (es) Uso de una cantidad terapéuticamente eficaz de un derivado clostridial para la preparación de una composición farmacéutica para el tratamiento de la incontinencia urinaria
MX2021011596A (es) Compuestos y composiciones como moduladores de se?alizacion tlr.
MX2020012543A (es) Diltiazem para usarse en el tratamiento de infecciones microbianas.
WO2019155360A3 (en) Pharmaceutical composition for treating bacterial and viral infections